Carperitide | CAS 89213-87-6 | Atrial Natriuretic Peptide (ANP) (1-28) (Research Use Only) | Knowlux

Product Description

Carperitide, CAS 89213-87-6, is a synthetic 28-amino-acid peptide corresponding to human atrial natriuretic peptide (ANP) (1-28), supplied by Knowlux for laboratory research use. The peptide is constrained by a single intramolecular disulfide bridge and carries a free C-terminal tyrosine carboxylate. The molecular formula is C127H203N45O39S3 and the molecular weight is 3080.44 g/mol (free peptide basis). Each lot is released with a lot-specific COA, MSDS and analytical traceability.

CAS and Salt Form Clarification: Carperitide is a case in which the CAS number applied in commercial listings and the salt form actually supplied frequently diverge, and the divergence affects both molecular formula and molecular weight. CAS 89213-87-6 is the free peptide registry, corresponding to formula C127H203N45O39S3 and a molecular weight of 3080.44. The acetate salt is most consistently assigned CAS 1366000-58-9, with molecular formula C129H207N45O41S3 (equivalently C127H203N45O39S3.C2H4O2) and a molecular weight of 3140.50. A substantial number of supplier catalogues, however, list the acetate salt under CAS 89213-87-6 while reporting the acetate molecular weight (3140.50) and the acetate formula (C129H207N45O41S3), or list the free peptide formula (C127H203N45O39S3) under the same CAS while describing the product as Carperitide Acetate. The 60 g/mol mass difference between free peptide and monoacetate is material for molarity calculations. Knowlux specifies the salt stoichiometry, acetate content, and water content per lot on the COA. Buyers should confirm whether the quoted material is reported on a free-peptide or acetate-salt basis before procurement, and should verify that the molecular weight on the COA reconciles to the declared salt form.

Structural Note: Carperitide corresponds to the full 28-residue human ANP sequence, with a disulfide bridge between Cys7 and Cys23 that defines the peptide's conserved loop structure. The C-terminus is free tyrosine (Tyr-OH), not amidated. The peptide contains a methionine residue at position 13, introducing a thioether side chain that is susceptible to oxidation to methionine sulfoxide; this is a principal degradation pathway for ANP and a consideration for formulation and storage. Unlike the N-terminally blocked or C-terminally amidated peptides in the Semax and Melanotan families, Carperitide retains both free termini, which influences its susceptibility to exopeptidase degradation in biological matrices.

Product Parameters

Product Details

1. Overview

Carperitide is a synthetic form of human atrial natriuretic peptide (ANP), a 28-residue cardiac hormone released from atrial myocytes in response to mechanical stretch and cardiac injury. It is the principal circulating natriuretic peptide in humans and functions as an endogenous regulator of blood volume and vascular tone. The peptide binds the natriuretic peptide receptor A (NPR-A), a particulate guanylyl cyclase, and elevates intracellular cyclic GMP, producing vasodilation, natriuresis, diuresis, and suppression of the renin-angiotensin-aldosterone system (RAAS). In clinical medicine, Carperitide is approved in Japan for acute decompensated heart failure. The material supplied under this specification is research-grade and is not intended for human administration. Knowlux supplies this compound strictly for laboratory investigation of NPR-A/cGMP signaling, cardiorenal physiology, and natriuretic peptide pharmacology.

2. Receptor Pharmacology and Selectivity

Carperitide is a high-affinity agonist at NPR-A (also designated GC-A), the receptor subtype that mediates the natriuretic and vasodilatory actions of ANP and BNP. NPR-A activation stimulates its intrinsic guanylyl cyclase activity, raising cGMP and activating protein kinase G-dependent signaling in vascular smooth muscle, renal tubules, and adrenal glomerulosa cells. The peptide also engages the clearance receptor NPR-C with lower affinity, a pathway that contributes to its metabolic clearance rather than its acute signaling effects. Selleck's pharmacological annotation lists NPR-A as the primary target for Carperitide and describes dose-dependent inhibition of endothelin-1 secretion, likely through a cGMP-dependent mechanism. The peptide's renal actions include inhibition of sodium reabsorption in the collecting duct and suppression of aldosterone release, while its vascular actions reduce preload and afterload. Unlike the bradykinin or melanocortin receptor agonists in this catalogue, Carperitide's signaling is cGMP-centric and does not proceed through Gq/11 or adenylyl cyclase. These descriptions are derived from published research and are provided for scientific reference only.

3. Research Applications

Published pharmacological characterizations and documented protocols describe the following research applications:

• NPR-A/GC-A binding and functional assays (cGMP accumulation in vascular and renal cell models)

• Cardiorenal physiology and natriuresis/diuresis mechanism studies

• RAAS suppression and aldosterone regulation research models

• Endothelin-1 secretion and vascular tone studies

• Peptide stability and methionine oxidation studies (Carperitide as a model for ANP degradation)

• Reference standard development for HPLC and LC-MS analytical methods

These descriptions are derived from published research and are provided for scientific reference only. They do not constitute clinical guidance or dosing recommendations.

Quality Control

Solubility and Handling

Solubility: Carperitide solubility is salt-form- and source-dependent, and the reported values span a wider range than for most peptides in this catalogue. For the free peptide (CAS 89213-87-6), ChemicalBook lists water solubility of 1 mg/mL. For the acetate salt, Selleck's batch-tested experimental data reports water solubility of 60 mg/mL, and a separate Selleck solubility page also lists a 100 mg/mL water value for a different batch or condition. MedChemExpress reports H2O solubility of 50 mg/mL (15.92 mM) with ultrasonic assistance for its acetate salt lot. The higher solubility of the acetate salt relative to the free peptide is consistent with the counter-ion's effect on dissolution and should be considered when selecting a solvent system. For practical stock preparation, water is the preferred solvent across salt forms; the acetate salt offers substantially greater aqueous solubility and is the more commonly supplied form for assay work. Prepare solutions fresh and aliquot to avoid repeated freeze-thaw cycles.

Handling Precautions: Use powder-handling containment (glove box or fume hood with particulate control). Avoid inhalation of fine powder. Wear nitrile gloves, lab coat, and eye protection. The Met13 thioether is susceptible to oxidation; BenchChem technical guidance recommends maintaining solutions at slightly acidic pH (around 4.0-5.5), preparing fresh solutions for each experiment, and adding an antioxidant such as methionine to competitively inhibit methionine oxidation where prolonged solution handling is unavoidable. The disulfide bridge is sensitive to reducing agents; avoid contact with dithiothreitol (DTT) or mercaptoethanol.

Storage and Stability

Documentation Support

Per lot: COA, MSDS, certificate of origin, HPLC chromatogram, and mass spectrometry data. Acetate content, water content, peptide content, and salt-form stoichiometry available on request. Custom specifications and third-party inspection can be arranged on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Carperitide is an approved medicinal product in certain jurisdictions for specific clinical indications (acute decompensated heart failure); however, the material offered under this specification is research-grade and is not intended for clinical use. The purchaser is responsible for verifying product specifications against their specific research requirements and for compliance with all applicable institutional, local, and national regulations governing research chemical acquisition, storage, and use. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.

Data Verification Notes: The free peptide molecular formula C127H203N45O39S3 and molecular weight 3080.44-3080.45 are confirmed by KEGG, USAN, ChemicalBook, Adooq, and Ace Therapeutics. The sequence SLRRSSCFGGRMDRIGAQSGLGCNSFRY with disulfide bridge Cys7-Cys23 is confirmed by KEGG, Ace Therapeutics, Adooq, and MedChemExpress. The acetate salt CAS 1366000-58-9, formula C129H207N45O41S3 (or C127H203N45O39S3.C2H4O2), and molecular weight 3140.50 are confirmed by MedChemExpress, Selleck, AbMole, Amerigo Scientific, and TargetMol. The CAS application inconsistency, in which the acetate salt is listed under free peptide CAS 89213-87-6 with either free peptide or acetate formula and molecular weight, is documented across ChemicalBook and MolCore listings and is explicitly addressed in the CAS Clarification section. Solubility values (1 mg/mL for free peptide; 50-100 mg/mL for acetate salt) are reported with their source conditions rather than reconciled into a single figure because the underlying measurements reflect different salt forms and dissolution techniques. Storage shelf-life divergence (-20C versus -80C for powder) is reported as-is; -80C is presented as the conservative archival option. The methionine oxidation liability and the pH 4.0-5.5 stabilization guidance are from BenchChem technical documentation.

Formatting Note: All formulas, sequences, and comparison operators use plain ASCII notation to prevent character corruption on the platform. Section headings, table alignment, and spacing follow the approved product detail pattern. No trailing spaces or non-breaking characters are used; tables use consistent pipe alignment.